OS Therapies Incorporated has reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of approximately $4.5 million for the quarter, compared to a loss of $1.6 million in the same period last year. For the first half of 2025, the net loss totaled approximately $8.4 million, up from $3.0 million in the first half of 2024. The increase in losses is attributed to heightened research and development expenses, which surged to $3.8 million for the six months ended June 30, 2025, compared to $0.8 million in the prior year. General and administrative expenses also rose significantly, reaching $6.0 million for the first half of 2025, up from $0.7 million in 2024.
The company’s total assets increased to approximately $10.3 million as of June 30, 2025, compared to $5.5 million at the end of 2024. This growth was primarily driven by the acquisition of intellectual property assets related to its lead product candidate, OST-HER2, which was completed in April 2025. The acquisition involved a total purchase price of $8 million, which included cash and stock considerations. The company also reported a significant increase in its additional paid-in capital, which rose to approximately $51.8 million from $35.1 million at the end of 2024.
Operationally, OS Therapies has made strides in its clinical development efforts. The company is currently conducting a Phase IIb clinical trial for OST-HER2, which has fully enrolled 41 patients as of October 2023. The company received positive feedback from the FDA regarding the trial's design and endpoints, and it plans to submit a Breakthrough Therapy Designation request. Additionally, the company has established a wholly-owned subsidiary, OS Animal Health Corp, to explore opportunities in veterinary oncology.
As of June 30, 2025, OS Therapies had cash reserves of approximately $2.8 million, down from $5.5 million at the end of 2024. The company has funded its operations primarily through the sale of convertible notes and Series A securities, raising a total of $37.1 million to date. However, the company has indicated that it will need to secure additional capital to continue its operations over the next 9 to 12 months. The outlook remains focused on advancing its clinical programs and seeking regulatory approvals, with the potential for significant market opportunities in treating osteosarcoma and other solid tumors.
About OS Therapies Inc
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.